Related Experiment Video
Updated: Oct 13, 2025
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Re-Evaluating Limitations in Atopic Dermatitis Meta-Analysis Is Important in Interpreting its Results : Limitations
Efstratios Vakirlis1, Aikaterini Tsentemeidou2, Stamatios Gregoriou3
1First Department of Dermatology and Venereology, School of Medicine, Aristotle University, 124 Delfon str, 54643, Thessaloníki, Greece. svakirlis@hotmail.com.
Abstract:
A recently published systematic review and meta-analysis concludes that topical calcineurin inhibitors (TCIs) used in atopic dermatitis (AD) increase risk of lymphoma. We believe this study has weaknesses that have not been adequately addressed by the authors and its results must therefore be interpreted with caution. According to study results only pimecrolimus used for AD was statistically significantly associated with lymphoma, and not TCIs in general. Unclear participant baseline immunocompetence and short follow-up duration limit the study's ability to detect malignancy risk. AD has been linked to an increased risk of lymphoma; however, cutaneous lymphoma can be misdiagnosed as AD, which makes it possible that the disease itself rather than treatment with TCIs could account for any increased likelihood of lymphoma in these patients. It is important that clinicians not be wrongfully made more reserved and insecure about prescribing TCIs in the future.
Insights
Topical calcineurin inhibitors (TCIs) for atopic dermatitis (AD) may not significantly increase lymphoma risk. Study limitations suggest caution when interpreting findings linking TCIs to lymphoma.
Area of Science:
- Dermatology
- Oncology
- Pharmacology
Background:
- A recent meta-analysis suggested topical calcineurin inhibitors (TCIs) increase lymphoma risk in atopic dermatitis (AD) patients.
- This interpretation warrants caution due to identified study limitations.
Discussion:
- The association was statistically significant only for pimecrolimus, not TCIs broadly.
- Participant baseline immunocompetence and follow-up duration were not adequately addressed.
- Atopic dermatitis itself is linked to increased lymphoma risk, complicating treatment-risk attribution.
- Misdiagnosis of cutaneous lymphoma as AD could skew results.
Key Insights:
- The reviewed meta-analysis has methodological weaknesses.
- The link between TCIs and lymphoma risk in AD requires further investigation.
- Current evidence necessitates careful interpretation to avoid undue clinical apprehension.
Outlook:
- Further research with robust methodologies is needed.
- Clinicians should maintain confidence in prescribing TCIs for AD management.
- Accurate diagnosis and long-term studies are crucial for understanding potential risks.
